Human Growth Hormone (hGH) Market by Application (Growth Hormone Deficiency, Prader-Willi Syndrome, Turner Syndrome, Small for Gestational Age, and Others), Route of Administration (Intravenous, Intramuscular, Subcutaneous, and Oral), and Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Clinics, and Online Pharmacy): Global Opportunity Analysis and Industry Forecast, 2021–2030
- ALL4676947
- 212 Pages
- September 2021
- Diagnostic and Biotech
There has been a considerate growth in the human growth hormone market in the recent years due to various factors like rise in adaptation of growth hormones for controlling the aging. Growth Hormone treatment is helping in improving the muscle strength body composition, physical function, and bone density. Growth hormones are also helpful in keeping a check over cardio vascular disorders and are used to decrease the levels of cholesterol in the body. Along with this, there has also been a rise in the disorders related to the growth hormones like Prader-Willi Syndrome, small for gestational age (SGA) and Turner Syndrome due to the wide adoption of sedentary lifestyles and increase consumption of alcohol. This surge is anticipated to propel the growth of the market in the near future. Moreover, rise in the disposable income in the developing economies is expected to create lucrative opportunities in the near future.
Rise in awareness regarding the effectiveness of growth hormones, demand for cost efficient growth hormone therapies; increase in prevalence of serious chronic diseases such as chronic kidney disease and growth retardation, and pituitary dysfunctions; and surge in compliance for growth hormone formulations are the major factors that drive the growth of the global human growth hormone market.
However, the unfavorable effects such as muscle pain, joint pain, and fluid retention associated with the use of synthetic growth hormones and high cost involved in the treatments using these growth hormones hinder the growth of the market. Moreover, stringent government approvals are expected to restrain the growth and development of the market in the coming years. On the contrary, rise in disposable income and surge in healthcare expenditure in developing economies is anticipated to create lucrative opportunities for the manufactures of growth hormones in the future.
The human growth hormone market is segmented on the basis of application, route of administration, distribution channel, and region. By application, it is categorized into growth hormone deficiency, Prader-Willi syndrome, Turner syndrome, small for gestational age, and others. By route of administration, it is classified into intravenous, intramuscular, subcutaneous, and oral. By distribution channel, it is divided into hospital pharmacy, retail pharmacy, clinic, and online pharmacy. Region wise, it is analyzed across North America, Asia-Pacific, Europe, and LAMEA.
The prominent players in the market have adopted various strategies for increasing their market share. These include expansion of their geographical presence through collaborations and partnerships and increase in investment in developing long-acting and effective products with lower adverse effects. Major players operating in the hGH market include Novo Nordisk, Merck & Co., Inc., Eli Lilly and Company, Pfizer Inc., Teva Pharmaceutical Industries Ltd, Novartis AG, AnkeBio Co. Ltd, F. Hoffmann-La Roche, Ipsen, and Ferring BV.
KEY BENEFITS FOR STAKEHOLDERS
• The study presents an in-depth analysis of the global human growth hormone market along with the current trends and future estimations from 2021 to 2030 to elucidate the imminent investment pockets.
• A comprehensive analysis of the factors that drive and restrict the market growth is provided.
• Identification of factors instrumental in changing the market scenario, rise in opportunities, and recognition of the key players that can influence this market on a global & regional scale are provided in the report.
• Key players are profiled, and their strategies are analyzed thoroughly to understand the competitive outlook of the market.
• The development strategies adopted by key manufacturers are enlisted to understand the competitive scenario of the market.
KEY MARKET SEGMENTS
• By Application
o Growth hormone deficiency
o Prader-Willi syndrome
o Turner syndrome
o Small for gestational age (SGA)
o Others
• By Route of Administration
o Oral
o Intravenous
o Intramuscular
o Subcutaneous
• By Distribution Channel
o Hospital pharmacy
o Retail pharmacy
o Online Pharmacy
• By Region
o North America
U.S.
Canada
Mexico
o Europe
Germany
France
UK
Italy
Spain
Rest of Europe
o Asia-Pacific
Japan
China
Australia
India
South Korea
Rest of Asia-Pacific
o LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
LIST OF KEY PLAYERS PROFILED IN THE REPORT
• Novo Nordisk
• Merck & Co.
• Eli Lilly & Company
• Pfizer Inc.
• Teva Pharmaceutical Industries
• Novartis AG
• Anhui Anke Biotechnology (Group) Co., Ltd
• Roche
• Ipsen
• Ferring BV
1.1.REPORT DESCRIPTION
1.2.KEY MARKET SEGMENTS
1.3.KEY BENEFITS
1.4.RESEARCH METHODOLOGY
1.4.1.Primary research
1.4.2.Secondary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.CXO PERSPECTIVE
CHAPTER 3:MARKET LANDSCAPE
3.1.MARKET DEFINITION AND SCOPE
3.2.KEY FINDINGS
3.2.1.Top investment pockets
3.2.2.Top winning strategies
3.3.PORTER'S FIVE FORCES ANALYSIS
3.3.1.Bargaining power of suppliers
3.3.2.Threat of new entrants
3.3.3.Threat of substitutes
3.3.4.Competitive rivalry
3.3.5.Bargaining power among buyers
3.4.MARKET SHARE ANALYSIS/TOP PLAYER POSITIONING
3.5.MARKET DYNAMICS
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
CHAPTER 4:HUMAN GROWTH HORMONE MARKET, BY APPLICATION
4.1.OVERVIEW
4.2.GROWTH HORMONE DEFICIENCY
4.2.1.Key market trends, Growth factors and opportunities
4.2.2.Market size and forecast by region
4.2.3.Market analysis by country
4.3.PRADER-WILLI SYNDROME
4.3.1.Key market trends, Growth factors and opportunities
4.3.2.Market size and forecast by region
4.3.3.Market analysis by country
4.4.TURNER SYNDROME
4.4.1.Key market trends, Growth factors and opportunities
4.4.2.Market size and forecast by region
4.4.3.Market analysis by country
4.5.SMALL FOR GESTATIONAL AGE (SGA)
4.5.1.Key market trends, Growth factors and opportunities
4.5.2.Market size and forecast by region
4.5.3.Market analysis by country
4.6.OTHERS
4.6.1.Key market trends, Growth factors and opportunities
4.6.2.Market size and forecast by region
4.6.3.Market analysis by country
CHAPTER 5:HUMAN GROWTH HORMONE MARKET, BY ROUTE OF ADMINISTRATION
5.1.OVERVIEW
5.2.ORAL
5.2.1.Key market trends, Growth factors and opportunities
5.2.2.Market size and forecast by region
5.2.3.Market analysis by country
5.3.INTRAVENOUS
5.3.1.Key market trends, Growth factors and opportunities
5.3.2.Market size and forecast by region
5.3.3.Market analysis by country
5.4.INTRAMUSCULAR
5.4.1.Key market trends, Growth factors and opportunities
5.4.2.Market size and forecast by region
5.4.3.Market analysis by country
5.5.SUBCUTANEOUS
5.5.1.Key market trends, Growth factors and opportunities
5.5.2.Market size and forecast by region
5.5.3.Market analysis by country
CHAPTER 6:HUMAN GROWTH HORMONE MARKET, BY DISTRIBUTION CHANNEL
6.1.OVERVIEW
6.2.HOSPITAL PHARMACY
6.2.1.Key market trends, Growth factors and opportunities
6.2.2.Market size and forecast by region
6.2.3.Market analysis by country
6.3.RETAIL PHARMACY
6.3.1.Key market trends, Growth factors and opportunities
6.3.2.Market size and forecast by region
6.3.3.Market analysis by country
6.4.ONLINE PHARMACY
6.4.1.Key market trends, Growth factors and opportunities
6.4.2.Market size and forecast by region
6.4.3.Market analysis by country
CHAPTER 7:HUMAN GROWTH HORMONE MARKET, BY REGION
7.1.OVERVIEW
7.2.NORTH AMERICA
7.2.1.Key market trends and opportunities
7.2.2.Market size and forecast by Application
7.2.3.Market size and forecast by Route of Administration
7.2.4.Market size and forecast by Distribution Channel
7.2.5.Market size and forecast by Country
7.2.6.US HUMAN GROWTH HORMONE MARKET
7.2.6.1.Market size and forecast by Application
7.2.6.2.Market size and forecast by Route of Administration
7.2.6.3.Market size and forecast by Distribution Channel
7.2.7.CANADA HUMAN GROWTH HORMONE MARKET
7.2.7.1.Market size and forecast by Application
7.2.7.2.Market size and forecast by Route of Administration
7.2.7.3.Market size and forecast by Distribution Channel
7.2.8.MEXICO HUMAN GROWTH HORMONE MARKET
7.2.8.1.Market size and forecast by Application
7.2.8.2.Market size and forecast by Route of Administration
7.2.8.3.Market size and forecast by Distribution Channel
7.3.EUROPE
7.3.1.Key market trends and opportunities
7.3.2.Market size and forecast by Application
7.3.3.Market size and forecast by Route of Administration
7.3.4.Market size and forecast by Distribution Channel
7.3.5.Market size and forecast by Country
7.3.6.FRANCE HUMAN GROWTH HORMONE MARKET
7.3.6.1.Market size and forecast by Application
7.3.6.2.Market size and forecast by Route of Administration
7.3.6.3.Market size and forecast by Distribution Channel
7.3.7.UK HUMAN GROWTH HORMONE MARKET
7.3.7.1.Market size and forecast by Application
7.3.7.2.Market size and forecast by Route of Administration
7.3.7.3.Market size and forecast by Distribution Channel
7.3.8.GERMANY HUMAN GROWTH HORMONE MARKET
7.3.8.1.Market size and forecast by Application
7.3.8.2.Market size and forecast by Route of Administration
7.3.8.3.Market size and forecast by Distribution Channel
7.3.9.SPAIN HUMAN GROWTH HORMONE MARKET
7.3.9.1.Market size and forecast by Application
7.3.9.2.Market size and forecast by Route of Administration
7.3.9.3.Market size and forecast by Distribution Channel
7.3.10.REST OF EUROPE HUMAN GROWTH HORMONE MARKET
7.3.10.1.Market size and forecast by Application
7.3.10.2.Market size and forecast by Route of Administration
7.3.10.3.Market size and forecast by Distribution Channel
7.4.ASIA-PACIFIC
7.4.1.Key market trends and opportunities
7.4.2.Market size and forecast by Application
7.4.3.Market size and forecast by Route of Administration
7.4.4.Market size and forecast by Distribution Channel
7.4.5.Market size and forecast by Country
7.4.6.JAPAN HUMAN GROWTH HORMONE MARKET
7.4.6.1.Market size and forecast by Application
7.4.6.2.Market size and forecast by Route of Administration
7.4.6.3.Market size and forecast by Distribution Channel
7.4.7.CHINA HUMAN GROWTH HORMONE MARKET
7.4.7.1.Market size and forecast by Application
7.4.7.2.Market size and forecast by Route of Administration
7.4.7.3.Market size and forecast by Distribution Channel
7.4.8.INDIA HUMAN GROWTH HORMONE MARKET
7.4.8.1.Market size and forecast by Application
7.4.8.2.Market size and forecast by Route of Administration
7.4.8.3.Market size and forecast by Distribution Channel
7.4.9.AUSTRALIA HUMAN GROWTH HORMONE MARKET
7.4.9.1.Market size and forecast by Application
7.4.9.2.Market size and forecast by Route of Administration
7.4.9.3.Market size and forecast by Distribution Channel
7.4.10.REST OF ASIA-PACIFIC HUMAN GROWTH HORMONE MARKET
7.4.10.1.Market size and forecast by Application
7.4.10.2.Market size and forecast by Route of Administration
7.4.10.3.Market size and forecast by Distribution Channel
7.5.LAMEA
7.5.1.Key market trends and opportunities
7.5.2.Market size and forecast by Application
7.5.3.Market size and forecast by Route of Administration
7.5.4.Market size and forecast by Distribution Channel
7.5.5.Market size and forecast by Country
7.5.6.BRAZIL HUMAN GROWTH HORMONE MARKET
7.5.6.1.Market size and forecast by Application
7.5.6.2.Market size and forecast by Route of Administration
7.5.6.3.Market size and forecast by Distribution Channel
7.5.7.SAUDI ARABIA HUMAN GROWTH HORMONE MARKET
7.5.7.1.Market size and forecast by Application
7.5.7.2.Market size and forecast by Route of Administration
7.5.7.3.Market size and forecast by Distribution Channel
7.5.8.SOUTH AFRICA HUMAN GROWTH HORMONE MARKET
7.5.8.1.Market size and forecast by Application
7.5.8.2.Market size and forecast by Route of Administration
7.5.8.3.Market size and forecast by Distribution Channel
7.5.9.REST OF LAMEA HUMAN GROWTH HORMONE MARKET
7.5.9.1.Market size and forecast by Application
7.5.9.2.Market size and forecast by Route of Administration
7.5.9.3.Market size and forecast by Distribution Channel
CHAPTER 8: COMPANY PROFILES
8.1.NOVO NORDISK
8.1.1.Company overview
8.1.2.Key Executives
8.1.3.Company snapshot
8.1.4.Operating business segments
8.1.5.Product portfolio
8.1.6.Business performance
8.1.7.Key strategic moves and developments
8.2.MERCK & CO.
8.2.1.Company overview
8.2.2.Key Executives
8.2.3.Company snapshot
8.2.4.Operating business segments
8.2.5.Product portfolio
8.2.6.Business performance
8.2.7.Key strategic moves and developments
8.3.ELI LILLY AND COMPANY
8.3.1.Company overview
8.3.2.Key Executives
8.3.3.Company snapshot
8.3.4.Operating business segments
8.3.5.Product portfolio
8.3.6.Business performance
8.3.7.Key strategic moves and developments
8.4.PFIZER INC.
8.4.1.Company overview
8.4.2.Key Executives
8.4.3.Company snapshot
8.4.4.Operating business segments
8.4.5.Product portfolio
8.4.6.Business performance
8.4.7.Key strategic moves and developments
8.5.TEVA PHARMACEUTICAL INDUSTRIES
8.5.1.Company overview
8.5.2.Key Executives
8.5.3.Company snapshot
8.5.4.Operating business segments
8.5.5.Product portfolio
8.5.6.Business performance
8.5.7.Key strategic moves and developments
8.6.NOVARTIS AG
8.6.1.Company overview
8.6.2.Key Executives
8.6.3.Company snapshot
8.6.4.Operating business segments
8.6.5.Product portfolio
8.6.6.Business performance
8.6.7.Key strategic moves and developments
8.7.ANHUI ANKE BIOTECHNOLOGY (GROUP) CO. LTD.
8.7.1.Company overview
8.7.2.Key Executives
8.7.3.Company snapshot
8.7.4.Operating business segments
8.7.5.Product portfolio
8.7.6.Business performance
8.7.7.Key strategic moves and developments
8.8.ROCHE
8.8.1.Company overview
8.8.2.Key Executives
8.8.3.Company snapshot
8.8.4.Operating business segments
8.8.5.Product portfolio
8.8.6.Business performance
8.8.7.Key strategic moves and developments
8.9.IPSEN
8.9.1.Company overview
8.9.2.Key Executives
8.9.3.Company snapshot
8.9.4.Operating business segments
8.9.5.Product portfolio
8.9.6.Business performance
8.9.7.Key strategic moves and developments
8.10.FERRING BV
8.10.1.Company overview
8.10.2.Key Executives
8.10.3.Company snapshot
8.10.4.Operating business segments
8.10.5.Product portfolio
8.10.6.Business performance
8.10.7.Key strategic moves and developments
TABLE 01.GLOBAL HUMAN GROWTH HORMONE MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 02.GROWTH HORMONE DEFICIENCY MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 03.PRADER-WILLI SYNDROME MARKET BY REGION 2020–2030 ($MILLION)
TABLE 04.TURNER SYNDROME MARKET BY REGION 2020–2030 ($MILLION)
TABLE 05.HUMAN GROWTH HORMONE MARKET FOR SMALL FOR GESTATIONAL AGE (SGA) MARKET BY REGION, 2020–2030 ($MILLION)
TABLE 06.HUMAN GROWTH HORMONE MARKET FOR OTHER APPLICATIONS BY REGION 2020–2030 ($MILLION)
TABLE 07.GLOBAL HUMAN GROWTH HORMONE MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 08.ORAL ROUTE OF ADMINSTRATION BY REGION, 2020–2030 ($MILLION)
TABLE 09.INTRAVENOUS ROUTE OF ADMINISTRATION MARKET BY REGION 2020–2030 ($MILLION)
TABLE 10.INTRAMUSCULAR ROUTE OF ADMINISTRATION MARKET BY REGION 2020–2030 ($MILLION)
TABLE 11.SUBCUTANEOUS ROUTE OF ADMINISTRATION MARKET BY REGION 2020–2030 ($MILLION)
TABLE 12.GLOBAL HUMAN GROWTH HORMONE MARKET, DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 13.HOSPITAL PHARMACY HUMAN GROWTH HORMONE MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 14.RETAIL PHARMACY HUMAN GROWTH HORMONE MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 15.ONLINE PHARMACY HUMAN GROWTH HORMONE MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 16.HUMAN GROWTH HORMONE MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 17.NORTH AMERICA HUMAN GROWTH HORMONE MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 18.NORTH AMERICA HUMAN GROWTH HORMONE MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 19.NORTH AMERICA HUMAN GROWTH HORMONE MARKET, DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 20.U.S. HUMAN GROWTH HORMONE MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 21.U.S. HUMAN GROWTH HORMONE MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 22.U.S. HUMAN GROWTH HORMONE MARKET, DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 23.CANADA HUMAN GROWTH HORMONE MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 24.CANADA HUMAN GROWTH HORMONE MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 25.CANADA HUMAN GROWTH HORMONE MARKET, DISTRIBUTION CHANNEL, 2020–2030($MILLION)
TABLE 26.MEXICO HUMAN GROWTH HORMONE MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 27.MEXICO HUMAN GROWTH HORMONE MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 28.MEXICO HUMAN GROWTH HORMONE MARKET, DISTRIBUTION CHANNEL, 2020–2030($MILLION)
TABLE 29.EUROPE HUMAN GROWTH HORMONE MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 30.EUROPE HUMAN GROWTH HORMONE MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 31.EUROPE HUMAN GROWTH HORMONE MARKET, DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 32.EUROPE HUMAN GROWTH HORMONE MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 33.FRANCE HUMAN GROWTH HORMONE MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 34.FRANCE HUMAN GROWTH HORMONE MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 35.FRANCE HUMAN GROWTH HORMONE MARKET, DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 36.UK HUMAN GROWTH HORMONE MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 37.UK HUMAN GROWTH HORMONE MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 38.UK HUMAN GROWTH HORMONE MARKET, DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 39.GERMANY HUMAN GROWTH HORMONE MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 40.GERMANY HUMAN GROWTH HORMONE MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 41.GERMANY HUMAN GROWTH HORMONE MARKET, DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 42.SPAIN HUMAN GROWTH HORMONE MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 43.SPAIN HUMAN GROWTH HORMONE MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 44.SPAIN HUMAN GROWTH HORMONE MARKET, DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 45.REST OF EUROPE HUMAN GROWTH HORMONE MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 46.REST OF EUROPE HUMAN GROWTH HORMONE MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 47.REST OF EUROPE HUMAN GROWTH HORMONE MARKET, DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 48.ASIA-PACIFIC HUMAN GROWTH HORMONE MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 49.ASIA-PACIFIC HUMAN GROWTH HORMONE MARKET, BY ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 50.ASIA-PACIFIC HUMAN GROWTH HORMONE MARKET, DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 51.ASIA-PACIFIC HUMAN GROWTH HORMONE MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 52.JAPAN HUMAN GROWTH HORMONE MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 53.JAPAN HUMAN GROWTH HORMONE MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 54.JAPAN HUMAN GROWTH HORMONE MARKET, DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 55.CHINA HUMAN GROWTH HORMONE MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 56.CHINA HUMAN GROWTH HORMONE MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 57.CHINA HUMAN GROWTH HORMONE MARKET, DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 58.INDIA HUMAN GROWTH HORMONE MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 59.INDIA HUMAN GROWTH HORMONE MARKET, BY ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 60.INDIA HUMAN GROWTH HORMONE MARKET, DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 61.AUSTRALIA HUMAN GROWTH HORMONE MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 62.AUSTRALIA HUMAN GROWTH HORMONE MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 63.AUSTRALIA HUMAN GROWTH HORMONE MARKET, DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 64.REST OF ASIA-PACIFIC HUMAN GROWTH HORMONE MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 65.REST OF ASIA-PACIFIC HUMAN GROWTH HORMONE MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 66.REST OF ASIA-PACIFIC HUMAN GROWTH HORMONE MARKET, DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 67.LAMEA HUMAN GROWTH HORMONE MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 68.LAMEA HUMAN GROWTH HORMONE MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 69.LAMEA HUMAN GROWTH HORMONE MARKET, DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 70.LAMEA HUMAN GROWTH HORMONE MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 71.BRAZIL HUMAN GROWTH HORMONE MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 72.BRAZIL HUMAN GROWTH HORMONE MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 73.BRAZIL HUMAN GROWTH HORMONE MARKET, DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 74.SAUDI ARABIA HUMAN GROWTH HORMONE MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 75.SAUDI ARABIA HUMAN GROWTH HORMONE MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 76.SAUDI ARABIA HUMAN GROWTH HORMONE MARKET, DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 77.SOUTH AFRICA HUMAN GROWTH HORMONE MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 78.SOUTH AFRICA HUMAN GROWTH HORMONE MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 79.SOUTH AFRICA HUMAN GROWTH HORMONE MARKET, DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 80.REST OF LAMEA HUMAN GROWTH HORMONE MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 81.REST OF LAMEA HUMAN GROWTH HORMONE MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 82.REST OF LAMEA HUMAN GROWTH HORMONE MARKET, DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 83.NOVO NORDISK: COMPANY SNAPSHOT
TABLE 84.NOVO NORDISK: OPERATING SEGMENTS
TABLE 85.NOVO NORDISK PLC: PRODUCT PORTFOLIO
TABLE 86.MERCK & CO.: COMPANY SNAPSHOT
TABLE 87.MERCK & CO. INC.: OPERATING SEGMENTS
TABLE 88.MERCK & CO. INC.: PRODUCT PORTFOLIO
TABLE 89.ELI LILLY AND COMPANY.: COMPANY SNAPSHOT
TABLE 90.ELI LILLY AND COMPANY.: OPERATING SEGMENTS
TABLE 91.ELI LILLY AND COMPANY.: PRODUCT PORTFOLIO:
TABLE 92.PFIZER INC.: COMPANY SNAPSHOT
TABLE 93.PFIZER INC.: OPERATING SEGMENTS
TABLE 94.PFIZER INC.: PRODUCT PORTFOLIO
TABLE 95.TEVA PHARMACEUTICAL INDUSTRIES.: COMPANY SNAPSHOT
TABLE 96.TEVA PHARMACEUTICAL INDUSTRIES.: OPERATING SEGMENTS
TABLE 97.TEVA PHARMACEUTICAL INDUSTRIES.: PRODUCT PORTFOLIO
TABLE 98.NOVARTIS AG: COMPANY SNAPSHOT
TABLE 99.NOVARTIS AG: OPERATING SEGMENTS
TABLE 100.NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 101.ANHUI ANKE BIOTECHNOLOGY (GROUP) CO., LTD.: COMPANY SNAPSHOT
TABLE 102.ANHUI ANKE BIOTECHNOLOGY (GROUP) CO., LTD.: OPERATING SEGMENTS
TABLE 103.ANHUI ANKE BIOTECHNOLOGY (GROUP) CO., LTD: PRODUCT PORTFOLIO
TABLE 104.ROCHE: COMPANY SNAPSHOT
TABLE 105.ROCHE: OPERATING SEGMENTS
TABLE 106.ROCHE: PRODUCT PORTFOLIO
TABLE 107.IPSEN: COMPANY SNAPSHOT
TABLE 108.IPSEN: PRODUCT SEGMENTS
TABLE 109.IPSEN: PRODUCT PORTFOLIO
TABLE 110.FERRING BV.: COMPANY SNAPSHOT
TABLE 111.FERRING BV.: OPERATING SEGMENTS
TABLE 112.FERRING BV: PRODUCT PORTFOLIO
Similar Reports
Complete report $6,100. DataPack (test volumes, sales forecasts, supplier shares) $3,950.
Summary
This comprehensive report contains 409 pages, 35 tables, and is designed to help current suppliers and potential market entrants identify and evaluate business opportunities emerging in the UK coagulation testing market duri...
- Publish Date: February 7, 2017
- $750
Complete report $9,600. DataPack (test volumes, sales forecasts, supplier shares) $6,200.
Summary
This comprehensive report contains 424 pages, 37 tables, and is designed to help current suppliers and potential market entrants identify and evaluate business opportunities emerging in the US coagulation testing market during the...
- Publish Date: February 7, 2017
- $750
This new report from VPGMarketResearch.com provides strategic assessments of major blood banking product suppliers and emerging market entrants. The report presents analyses of major current and emerging suppliers in terms of their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements, and business strategies.
Con...
- Publish Date: February 7, 2017
- $750
